Literatuurreferenties
1. 011701WB June 2001 EU-SmPC NuvaRing Dutch version.doc
2. Roumen FJME, et al. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 2001; 16: 469-475.
3. Dieben TOM, et al. Efficacy, cycle control and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002; 100: 585-593.
4. NHG Standaard Hormonale Anticonceptie.
5. Dukes MNG. Hormonal Contraceptives. In: Dukes MNG, Aronson JK (eds.) Meyler's side effect of drugs. Amsterrdam: Elsevier, 2000: 1405-1447.
6. Hatcher RA, et al. Contraceptive Technology. New York: Irvington Publishers, 1994: 113.
7. Farmacotherapeutisch rapport ethinylestradiol/etonogestrel, vaginale ring (Nuvaring®).
8. Bjarnadóttir RI, et al. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinylestradiol. Am J Obstet Gynecol 2002: 186: 389-395.
9. USPDI. Drug Information for the health care professional 2001, 21e edition.
10. Vandenbroucke JP, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001: 344: 1527-1535.
